BAFNAPHARM
11.5
2019-01-04
BAFNA PHARMACEUTICALS LTD.
Profitability metrics STANDALONE CONSOLIDATED
Asset Turnover 0.5929 0.5464
Current ratio 2.13 1.73
WC days 217.62 188.43
EBITDA (%) -5.04 -4.81
FCF (Rs Cr.) -5.98 0
ROCE (%) -8.57 -9.01
ROE (%) -40.59 -44.13

Solvency metrics STANDALONE CONSOLIDATED
Cash Ratio 0.07 0.05
Div. payout (%) 0 0
Int. Coverage -1.1 -1.1
LT D/E 1.15 1.23
Solvency Ratio -0.28 -0.27

Valuation STANDALONE CONSOLIDATED
Beta 0.9834 0.9834
Div. yield (%) 0 0
EV (Rs Cr.) 110.09 109.84
P/BV 1.63 1.75
P/E 0 0
PEG 0 0
P/S 0.88 0.88

Balance sheet metrics STANDALONE CONSOLIDATED
BV/share 17.13 16.03
3Y growth BV/s (%) -56 -58
Cash (Rs Cr.) 2.7 2.95
Total Debt (Rs Cr.) 46.54 46.54
Net block (Rs Cr.) 39.94 44.9

P&L metrics STANDALONE CONSOLIDATED
DPS 0 0
EPS -6.95 -7.08
Net Income (Rs Cr.) -16.45 -16.74
Operating profit (Rs Cr.) -5.05 -5.09
No. of o/s shares 2.366 2.366
Revenue (Rs Cr.) 75.6 75.6
Total Income (Rs Cr.) 76.83 76.89

Cash Flow metrics STANDALONE CONSOLIDATED
CEPS (%) -555 0
3Y growth CEPS -2.09 0
CFF (Rs Cr.) -30.65 0
CFI (Rs Cr.) 37.79 0
CFO (Rs Cr.) -13.13 0
FCF (Rs Cr.) -5.98 0
3Y growth Op. CF (%) -239 0

Growth metrics STANDALONE CONSOLIDATED
3Y growth dividends (%) 0 0
1Q growth EBITDA (%) 0 0
3Y growth EBITDA (%) -116 -114
4Q growth EBITDA (%) 0 0
1Q growth EPS (%) 0 0
3Y growth EPS (%) -312 -313
4Q growth EPS (%) 0 0
3Y growth Net inc. (%) -369 -371
1Y growth Op. CF (%) -403 0
1Q growth revenue (%) 0 0
3Y growth revenue (%) -25 -23
4Q growth revenue (%) 0 0